Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 1;29(5):1130-1140.
doi: 10.1093/annonc/mdy102.

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions

R I Haddad  1 , M Posner  2 , R Hitt  3 , E E W Cohen  4 , J Schulten  5 , J-L Lefebvre  6 , J B Vermorken  7
Affiliations

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions

R I Haddad et al. Ann Oncol. .

Abstract

Background: The value of induction chemotherapy (ICT) remains under investigation despite decades of research. New advancements in the field, specifically regarding the induction regimen of choice, have reignited interest in this approach for patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Sufficient evidence has accumulated regarding the benefits and superiority of TPF (docetaxel, cisplatin, and fluorouracil) over the chemotherapy doublet cisplatin and fluorouracil. We therefore sought to collate and interpret the available data and further discuss the considerations for delivering ICT safely and optimally selecting suitable post-ICT regimens.

Design: We nonsystematically reviewed published phase III clinical trials on TPF ICT in a variety of LA SCCHN patient populations conducted between 1990 and 2017.

Results: TPF may confer survival and organ preservation benefits in a subgroup of patients with functionally inoperable or poor-prognosis LA SCCHN. Additionally, patients with operable disease or good prognosis (who are not candidates for organ preservation) may benefit from TPF induction in terms of reducing local and distant failure rates and facilitating treatment deintensification in selected populations. The safe administration of TPF requires treatment by a multidisciplinary team at an experienced institution. The management of adverse events associated with TPF and post-ICT radiotherapy-based treatment is crucial. Finally, post-ICT chemotherapy alternatives to cisplatin concurrent with radiotherapy (i.e. cetuximab or carboplatin plus radiotherapy) appear promising and must be investigated further.

Conclusions: TPF is an evidence-based ICT regimen of choice in LA SCCHN and confers benefits in suitable patients when it is administered safely by an experienced multidisciplinary team and paired with the optimal post-ICT regimen, for which, however, no consensus currently exists.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Current standard-of-care paradigm in LA SCCHN. *ICT→RT is only an accepted standard approach for larynx preservation in locoregionally advanced larynx and hypopharynx cancer. ICT, induction chemotherapy; LA SCCHN, locally advanced squamous cell carcinoma of the head and neck.
Figure 2.
Figure 2.
TPF versus PF in two different patient cohorts (TAX 323/EORC 24971 and TAX 324). 5-FU, fluorouracil; HR, hazard ratio; mOS, median overall survival; PF, cisplatin plus 5-FU; RT, radiotherapy; TPF, docetaxel, cisplatin, and 5-FU. From Refs [4, 5]. Copyright © 2007 Massachusetts Medical Society. Reprinted with permission.
See this image and copyright information in PMC

References

    1. Ma J, Liu Y, Yang X. et al. Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis. World J Surg Oncol 2013; 11: 67. 67-7819-11-67. - PMC - PubMed
    1. The Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG. et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685–1690. - PubMed
    1. Paccagnella A, Ghi MG, Loreggian L. et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010; 21(7): 1515–1522. - PubMed
    1. Vermorken JB, Remenar E, van Herpen C. et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357(17): 1695–1704. - PubMed
    1. Posner MR, Hershock DM, Blajman CR. et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357(17): 1705–1715. - PubMed

Publication types

MeSH terms